Fig. 6: Inhibition of SARS-CoV-2 replicons in 293T cells. | Nature Microbiology

Fig. 6: Inhibition of SARS-CoV-2 replicons in 293T cells.

From: Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

Fig. 6: Inhibition of SARS-CoV-2 replicons in 293T cells.The alternative text for this image may have been generated using AI.

a, Dose–response curves of replicon inhibition by RAY1216 and PF-07321332. Percentage inhibition (mean ± s.d., n = 3) of replicons bearing indicated Mpro mutations was assessed by measuring replicon-expressed luciferase activity. b, Tested mutation positions mapped onto the RAY1216:Mpro inhibition complex structure. Hydrogen bonds between RAY1216 and mutated residues are indicated by dashed lines; transparent surfaces mark residues engaging hydrophobic contact to RAY1216.

Source data

Back to article page